QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Cardium Therapeutics, Inc. (CXM) Builds A Diverse Approach To The Medical And Health Marketplace 0 comments
    Mar 20, 2013 10:46 AM | about stocks: CXM

    Cardium Therapeutics is implementing a broad-based strategy of engaging the medical and health marketplace, focused on opportunities offering a clear path to monetization.

    Generx, Cardium's lead clinical development product candidate, is unique in its ability to stimulate the growth of blood vessels in the heart for patients with insufficient blood flow as the result of cardiovascular disease. Instead of invasive and terribly expensive operations such as coronary angioplasty or bypass surgery, or taking traditional anti-anginal drugs that simply treat the pain, Cardium's Generx product candidate offers a potential non-surgical and less expensive therapeutic option. This is of special importance in many developing countries where technology limitations and cost factors result in reduced treatment options for patients. Generx has already progressed through four randomized clinical studies at over 100 medical centers in the U.S. and Europe and has commenced the ASPIRE Phase 3 registration study at up to nine leading cardiology centers in Russia.

    Excellagen, Cardium's FDA-cleared, professional use treatment for neuropathic diabetic foot ulcers and other dermal wounds, offers an especially easy-to-use treatment that has shown a statistically significant relative improvement in the rate of healing (reduction in wound radius) during the first two weeks following a one-time application compared to patients receiving standard of care therapy. Genedexa is the first planned product extension of the Excellagen platform. Internationally, Cardium plans to obtain a CE Mark for the potential marketing and sale of Excellagen in the European Union, which consists of 27 member countries.

    The company's portfolio extends into the healthy lifestyle arena with the recent purchase of To Go Brands, which develops and sells a portfolio of over 25 products including nutraceutical powder mixes, supplements, and chews to support healthy lifestyles. The product line contains 100% natural antioxidant-rich drink mixes with organic ingredients in convenient stick packs, designed to pour directly into a water bottle, mix packages for home use, as well as capsule-based dietary supplements.

    For more information visit, cardiumthx.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: CXM
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.